We are excited to announce major milestones for CSL Behring’s Hizentra app, which supports patients taking Hizentra with medication reminders, record management, infusion tracking and more. The latest version of the app introduces exciting new capabilities and an updated design. The update also expands the app's footprint geographically, reaching new markets in Latin America and Canada, in addition to the existing regions of the U.S. and Japan.
The latest version of the Hizentra app brings additional functionality, including:
The Hizentra app is now available in the U.S., Japan, Canada, Chile and Argentina. Because the app is built on the BrightInsight® Platform, our team was able to localize the app features, graphics and language quickly for these new regions, while meeting security, privacy and regulatory compliance across geographies.
This latest expansion of the Hizentra app demonstrates BrightInsight’s ability to efficiently help our biopharma partners launch and scale their drug companion apps geographically in an agile and compliant manner.
This global app expansion was driven by significant adoption and high retention rates among users of the U.S. Hizentra app. Specifically:
This app is also a terrific proof point of how companion apps can capture valuable real-world data for biopharma companies. For example, 250k infusions have been recorded in the Hizentra app to date.
For more information on CSL Behring’s Hizentra app, read our case study.
Source 1: Attentive “2022 Mobile Customer Engagement Benchmark Report”